Screener / SEC EDGAR /CIK 0001076930 /10-K filed Feb 23, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Technology · Miscellaneous Electrical Machinery, Equipment & Supplies

Novanta Inc NOVT

Compare with peers Embed
The 10-K against last year's

120 changes: 21 added, 11 removed, 88 reworded

10-K Feb 23, 2026 vs Feb 25, 2025

10-K 0001193125-26-064230 (Feb 23, 2026) vs 10-K 0000950170-25-026131 (Feb 25, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

143 paragraphs · 3 new · 43 reworded · 1 gone · 10-K Feb 23, 2026 against Feb 25, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 114 · 49% changed Every version of it
There has been increased public focus and scrutiny from investors, governmental and nongovernmental organizations, customers, and other stakeholders and third parties on corporate sustainability and responsibility practices in recent years, including with respect to global warming and climate change, diversity, equity and inclusion, and labor and human rights, among other similar issues. Both the standard setting and regulatory landscapes are evolving and extremely complex, presenting significant compliance challenges. Such increased complexity and scrutiny may result in increased costs, increased risk of litigation or reputational damage relating to our sustainability and responsibility practices or performance, enhanced compliance or disclosure obligations, or other adverse impacts on our business, financial condition or results of operations. Many different governmental organizations are promulgating reporting standards and rules that focus on a myriad of sustainability topics, including new reporting requirements in various jurisdictions. For example, we may be subject to, among others, the requirements of the EU Corporate Sustainability Reporting Directive, other EU directives, EU and EU member state regulations, various disclosure requirements (such as information on greenhouse gas emissions, climate risks, use of offsets, and emissions reduction claims) from the State of California as well as the SEC’s stayed rule on climate related disclosures, if put in place. Additional local, state, federal and international laws and rules with respect to sustainability and corporate responsibility matters may be enacted in the future and the extent and scope of their requirements and impacts on our business are unknown. As we continue to focus on developing our sustainability and corporate responsibility practices, such practices may not meet the standards of all of our stakeholders, and both advocates and opponents of such practices are increasingly resorting to a range of activism forms, including media campaigns, shareholder proposals, and litigations, to advance their perspectives. There has similarly been an increase in activism and litigation alleging that corporate diversity, equity and inclusion programs may discriminate against certain groups. Many of our large, global customers are also committing to long-term targets to reduce greenhouse gas emissions within their supply chains. If we are unable to support customers in achieving these reductions, we may lose revenue if our customers find other suppliers who are better able to support such reductions. A failure, or perceived failure, to respond to expectations of all key stakeholders could cause harm to our business and reputation and have a negative impact on the market price of our common shares. Further, organizations that provide information to investors on corporate governance and related matters have developed rating processes for evaluating companies on sustainability and corporate responsibility matters. Such ratings are used by some investors to inform their investment or voting decisions. Unfavorable ratings could lead to negative investor sentiment towards us and/or our industry, which could have a negative impact on our access to and costs of capital.
Paragraph 56 · 49% changed Every version of it
Disruptions in the supply of certain raw materials, key components and or other goods from our suppliers, including limited or single source suppliers, is possible and could have adversely affected the results of a significant adverse effect on our business operations, and could damage our relationships with customers. customers, or even lead to permanent loss of customer orders.
Paragraph 44 · 46% changed Every version of it
Further, our ability to maintain and increase the profitability of acquired businesses will depend on our ability to manage and control operating expenses and to generate and sustain increased levels of revenue. Our expectations to achieve more consistent and predictable levels of revenue and to increase profitability as a result of any acquisition may not be realized. Such revenues and profitability may even decline as we integrate newly acquired operations into our existing businesses. We may fail to identify inherent weaknesses in acquired businesses or misinterpret market and technology trends and growth potentials during our acquisition due diligence process. If revenues of acquired businesses decline or grow more slowly than we anticipate, or if their operating expenses are higher than we expect, we may not be able to sustain or increase their profitability, in which case we may not be able to realize the expected return on our investments, our financial condition will suffer, and our stock price could decline. In addition, through our acquisitions, we may assume liabilities, losses or costs for which we are not indemnified or insured or for which our indemnity or insurance is inadequate. Any such liabilities may have a material adverse effect on our financial position or results of operations.
Paragraph 7 · 44% changed Every version of it
During a period of increasing demand and rapid growth, we must be able to increase manufacturing capacity quickly. Our inability to quickly increase production in response to a surge in demand has prompted customers to look for alternative sources of supply and has left our customers without a supply, both of which have harmed our reputation and made it difficult for us to retain our existing customers or to obtain new customers. If this inability to increase production continues or worsens, it could have a material adverse effect on our business.
Paragraph 66 · 42% changed Every version of it
Some of our products and the related sales and marketing development activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act (the “FDCA”), by comparable agencies in foreign countries, and by other regulatory agencies and governing bodies. Under the FDCA, medical devices must receive FDA clearance or approval or an exemption from such clearance or approval before they can be commercially marketed in the U.S. In the EU, medical devices must comply with the EU Medical Devices Regulation, which repeals and replaces the EU Medical Devices Directive. All medical devices placed on the market in the EU must meet the general safety and performance requirements laid down in Annex I to the EU Medical Devices Regulation, including the requirement that a medical device must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended purpose. Medical devices must be safe and effective and must not compromise the clinical condition or safety of patients, or the safety and health of users and – where applicable – other persons, provided that any risks which may be associated with their use constitute acceptable risks when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety, taking into account the generally acknowledged state of the art. To demonstrate compliance with the general safety and performance requirements, medical devices must undergo a conformity assessment procedure, which varies according to the type of medical device and its risk classification. Except for low risk medical devices (Class I), where the manufacturer can self-assess the conformity of its products with the general safety classification, and performance requirements (except for any parts which relate to sterility, metrology or reuse aspects), a conformity assessment procedure requires the intervention of a notified body. The notified body would typically audit and examine the technical file and the quality system for the manufacture, design and final inspection of our devices. If satisfied that the relevant product conforms to the relevant general safety and performance requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the European Conformity (“CE”) mark to the device, which allows the device to be placed on the market throughout the EU. If we fail to comply with applicable laws and regulations, we would be unable to affix the CE mark to our products, which would prevent us from selling them within the EU. The aforementioned EU rules are generally applicable in the EEA. Non-compliance with the above requirements would also prevent us from selling our products in these countries.
Paragraph 65 · 38% changed Every version of it
Some of our products products, and the related sales development, manufacturing and marketing development commercialization activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act (the “FDCA”), and by comparable agencies in foreign countries, and by or other regulatory agencies and governing bodies. bodies in the U.S. and around the world. Under the FDCA, medical devices must receive FDA clearance or approval or an exemption from such clearance or approval before they can be commercially marketed in the U.S. In the EU, medical devices must comply with the EU Medical Devices Regulation, which repeals and replaces the EU Medical Devices Directive. All medical devices placed on the market in the EU must meet including the general safety and performance requirements laid down in Annex I to the EU Medical Devices Regulation, including the requirement which require that a medical device must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended purpose. Medical devices must be safe and effective and must not compromise the clinical condition or safety of patients, or the safety and health of users and – where applicable – other persons, provided that any risks which may be associated with their use constitute acceptable risks when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety, taking into account the generally acknowledged state of the art. To demonstrate compliance with the general safety and performance requirements, medical devices must undergo a conformity assessment procedure, which varies according to the type of medical device and its risk classification. Except for low risk medical devices (Class I), where the manufacturer can self-assess the conformity of its products with the general safety and performance requirements (except for any parts which relate to sterility, metrology or reuse aspects), a conformity assessment procedure requires the intervention of a notified body. The notified body would typically audit and examine the technical file and the quality system for the manufacture, design and final inspection of our devices. If satisfied that the relevant product conforms to the relevant general safety and performance requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the European Conformity (“CE”) mark to the device, which allows the device to be placed on the market throughout the EU. If we fail to comply with applicable laws and regulations, we would be unable to affix the CE mark to our products, which would prevent us from selling them within the EU. The aforementioned EU rules are generally applicable in the EEA. Non-compliance with the above requirements would also prevent us from selling our products in these countries.
Paragraph 93 · 37% changed Every version of it
We are also subject to regulatory oversight, including comparable enforcement mechanisms, in the markets we serve. We compete in many markets in which we and our customers must comply with federal, state, local and international regulations, such as environmental, health and safety and food and drug regulations. We develop, configure and market our products to meet customer needs created by those regulations. Any significant changes in government regulations could reduce demand for our products or increase our expenses, which in turn could adversely affect our business, financial condition and results of operations.
Paragraph 82 · 31% changed Every version of it
•the federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to be deemed to have committed a violation;

MD&A

139 paragraphs · 18 new · 57 reworded · 10 gone · 10-K Feb 23, 2026 against Feb 25, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 105 · 50% changed
Substantially all of our revenue is recognized at a point in time, upon shipment, rather than over time. At the request of our customers, we may perform professional services, generally for the maintenance and repair of products previously sold to those customers and for engineering services. Professional services are less than 3% of our consolidated revenue. Revenue is typically recognized at a point in time when control transfers to the customer upon completion of professional services. These services generally involve a single distinct performance obligation. The consideration expected to be received in exchange for such services is normally the contractually stated amount.
Paragraph 49 · 49% changed
We recorded restructuring, acquisition and related costs of $22.7 million in 2025, versus $13.7 million in 2024, versus $12.8 million in 2023. 2024. The increase is was primarily attributable to restructuring costs incurred in connection with the 2025 restructuring program, which was undertaken to regionalize our manufacturing footprint and establishing manufacturing centers of excellence to better serve our customers, as a result of our 2024 well as higher acquisition and lower restructuring related charges. expenses associated with a 2025 acquisition. These increases were partially offset by a gain on the sale of an owned facility.
Paragraph 58 · 49% changed
Foreign exchange transaction gains (losses) were $(2.2) million in 2025, and nominal in 2024, 2023, 2024. The increase in net foreign exchange transaction losses was primarily due to changes in the value of the U.S. Dollar against the British Pound and 2022. Euro.
Paragraph 39 · 48% changed
Medical Solutions segment gross profit for 2024 increased utilization and productivity, partially offset by $19.2 million, or 11.2%, versus 2023, primarily margin declines due to an increase in revenue. Medical Solutions temporary cost increases incurred as part of our regionalized manufacturing strategy and lower factory utilization for precision medicine products. In addition, 2024 gross profit margin was 41.4% for 2024, versus included a gross profit margin of 44.7% for 2023. The decrease in gross profit margin was primarily due to an one-time inventory related charge associated with a precision medicine product, product line closure and the dilutive effect amortization of inventory fair value adjustment associated with our 2024 acquisition, partially offset by improved factory utilization in our advanced surgery products. acquisition.
Paragraph 15 · 48% changed
•improving •strengthening our existing operations operational performance to expand profit margins and improve enhance customer satisfaction by implementing deploying lean manufacturing principles, principles and advancing strategic sourcing initiatives across our major production sites, while regionalizing our manufacturing footprint and optimizing establishing manufacturing centers of excellence to achieve greater efficiency and limiting the growth of our fixed cost base; reduce overall production complexity; and
Paragraph 95 · 46% changed
As of December 31, 2024, 2025, future interest payments under our Senior Credit Facilities are estimated to be approximately $52.7 $33.6 million through maturity based on the current contractual term, with $24.4 $8.1 million payable within the next twelve months. These estimates are based on current interest rates on floating rate obligations, as defined in the Third Amended and Restated Credit Agreement, for the remainder of the contractual life of both the term loan and outstanding borrowings under the revolving credit facility, and the current commitment fee rate was used for the unused commitments under the revolving credit facility as of December 31, 2024. These estimates also assume only quarterly term loan payments are made and outstanding revolving credit facility remains unchanged throughout the remainder of the contractual term. Actual future interest payments will vary due to changes in our debt level and interest rates. See Note 11, “Debt,” in the Consolidated Financial Statements for further details of our debt obligations and the timing of expected future payments.
Paragraph 70 · 40% changed
In February 2020, September 2025, our Board of Directors approved a share repurchase plan (the “2020 “2025 Repurchase Plan”) authorizing the repurchase of $50.0 $200.0 million worth of common shares, effective after our prior repurchase plan was completed. Share repurchases shares. No shares have been made repurchased under the 2020 2025 Repurchase Plan pursuant to Rule 10b-18 under the Securities Exchange Act of 1934. During the year ended December 31, 2022, we repurchased 4 thousand shares for an aggregate purchase price of $0.5 million at an average price of $116.95 per share under the 2020 Repurchase Plan. No shares were repurchased during the years ended December 31, 2024 or 2023. As as of December 31, 2024, we had $49.5 million available for share repurchases under the 2020 Repurchase Plan. 2025.
Paragraph 94 · 40% changed
As of December 31, 2024, 2025, we had $70.4 $74.0 (€63.1) million (€67.6 million) term loan and $348.8 million revolving credit facility borrowings outstanding under the Euro Term Loans and $75.0 million outstanding under the U.S. Term Loans. As of December 31, 2025, we had no outstanding revolver borrowings under our Senior Credit Facilities. The term loan is payable in Euro Term Loans require quarterly installments scheduled principal repayments of approximately €1.1 million ($1.2 ($1.3 million) with that began in September 2025, and the final installment remaining principal balance of €58.5 €42.7 million ($61.0 ($50.1 million) is due upon maturity in March 2027. Borrowings under June 27, 2030, if the revolving credit maturity date of the term loan facility are is not otherwise extended. The U.S. Term Loans require quarterly principal payments of $0.5 million beginning in September 2026, increasing to $0.9 million in September 2027, with the remaining principal balance of $61.9 million due at on June 27, 2030, if the maturity in March 2027. date of the term loan facility is not otherwise extended.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors352 words changed in this paragraph; it is 40% similar to last year's version.
There has been increased public focus and scrutiny from investors, governmental and nongovernmental organizations, customers, and other stakeholders and third parties on corporate sustainability and responsibility practices in recent years, including with respect to global warming and climate change, diversity, equity and inclusion, and labor and human rights, among other similar issues. Both the standard setting and regulatory landscapes are evolving and extremely complex, presenting significant compliance challenges. Such increased complexity and scrutiny may result in increased costs, increased risk of litigation or reputational damage relating to our sustainability and responsibility practices or performance, enhanced compliance or disclosure obligations, or other adverse impacts on our business, financial condition or results of operations. Many different governmental organizations are promulgating reporting standards and rules that focus on a myriad of sustainability topics, including new reporting requirements in various jurisdictions. For example, we may be subject to, among others, the requirements of the EU Corporate Sustainability Reporting Directive, other EU directives, EU and EU member state regulations, various disclosure requirements (such as information on greenhouse gas emissions, climate risks, use of offsets, and emissions reduction claims) from the State of California as well as the SEC’s stayed rule on climate related disclosures, if put in place. Additional local, state, federal and international laws and rules with respect to sustainability and corporate responsibility matters may be enacted in the future and the extent and scope of their requirements and impacts on our business are unknown. As we continue to focus on developing our sustainability and corporate responsibility practices, such practices may not meet the standards of all of our stakeholders, and both advocates and opponents of such practices are increasingly resorting to a range of activism forms, including media campaigns, shareholder proposals, and litigations, to advance their perspectives. There has similarly been an increase in activism and litigation alleging that corporate diversity, equity and inclusion programs may discriminate against certain groups. Many of our large, global customers are also committing to long-term targets to reduce greenhouse gas emissions within their supply chains. If we are unable to support customers in achieving these reductions, we may lose revenue if our customers find other suppliers who are better able to support such reductions. A failure, or perceived failure, to respond to expectations of all key stakeholders could cause harm to our business and reputation and have a negative impact on the market price of our common shares. Further, organizations that provide information to investors on corporate governance and related matters have developed rating processes for evaluating companies on sustainability and corporate responsibility matters. Such ratings are used by some investors to inform their investment or voting decisions. Unfavorable ratings could lead to negative investor sentiment towards us and/or our industry, which could have a negative impact on our access to and costs of capital.

Source: Item 1A, 10-K 0001193125-26-064230 vs Item 1A, 10-K 0000950170-25-026131

MD&A144 words changed in this paragraph; it is 47% similar to last year's version.
As of December 31, 2024, 2025, we had $70.4 (€67.6) $74.0 (€63.1) million term loan outstanding under the Euro Term Loans and $348.8 $75.0 million outstanding under the U.S. Term Loans. As of December 31, 2025, we had no outstanding revolver borrowings outstanding under our Senior Credit Facilities. The borrowings outstanding under the Senior Fourth Amended and Restated Credit Facilities Agreement bear interest at rates based on (a) the Base Rate, as Rate (as defined in the Fourth Amended and Restated Credit Agreement, Agreement) plus a margin ranging between 0.00% to zero and 0.75% per annum, determined by reference to the our consolidated leverage ratio, or (b) the Term SOFR Screen Rate, the Alternative Currency Daily Rate SOFR, SONIA or the Alternative Currency Term Rate, EURIBOR, as defined in the Credit Agreement, applicable, plus a margin ranging between 0.75% 1.00% and 1.75% per annum, determined by reference to our consolidated leverage ratio. In addition, we are obligated to pay a commitment fee on the unused portion of the revolving credit facility, ranging between 0.20% and 0.30% per annum, determined by reference to our consolidated leverage ratio. As of December 31, 2024, we had outstanding borrowings under the Senior Credit Facilities denominated in Euro and U.S. Dollars of $86.6 million and $332.6 million, respectively.

Source: Item 7, 10-K 0001193125-26-064230 vs Item 7, 10-K 0000950170-25-026131

Accounting Policies143 words changed in this paragraph; it is 35% similar to last year's version.
In October 2023, September 2025, the FASB issued ASU 2023-06, “Disclosure Improvements: Codification Amendments in Response to SEC’s Disclosure Update 2025-06, “Intangibles-Goodwill and Simplification Initiative.” ASU 2023-06 clarifies or improves disclosure and presentation requirements of a variety of topics, which allow users to easily compare entities subject Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the SEC’s existing Accounting for Internal-Use Software.” ASU 2025-06 eliminates references to prescriptive software development stages and requires capitalization of internal-use software costs once management commits funding and project completion is probable, while also updating disclosure requirements to align with those entities that were not previously subject to such requirements Property, Plant, and align the requirements in the FASB Accounting Standards Codification with the SEC’s regulations. Equipment guidance. The effective date for each amendment amendments in ASU 2023-06 will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early 2025-06 are effective for annual periods beginning after December 15, 2027. Early adoption prohibited. is permitted. The Company is currently evaluating the impact of ASU 2023-06 2025-06 on its consolidated financial statement disclosures.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001193125-26-064230 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0000950170-25-026131

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of NOVT's Risk Factors and MD&A, 10-K Feb 23, 2026 against 10-K Feb 25, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
On June 16, 2025, an amendment to the UK Medical Devices Regulations became applicable, and it strengthened the post-market surveillance requirements for medical devices in Great Britain. In addition, the MHRA launched a consultation from November 14, 2024 to January 5, 2025 on proposals to update the pre-market requirements for medical devices in Great Britain.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
additional tax obligations in countries that choose to adopt new tax requirements such as the proposed Pillar Two rules. Further, such tax law changes may cause our effective tax rate to fluctuate between periods.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedRisk Factors
In addition, the market price of our common shares may be influenced by the Units. For example, the market price of our common shares could become more volatile and could be depressed by (i) investors’ anticipation of the potential resale in the market of a substantial number of our additional common shares received upon settlement of the purchase contracts that are a component of the Units; (ii) possible sales of our common shares by investors who view the Units as a more attractive means of equity participation in us than owning our common shares; and (iii) hedging or arbitrage trading activity that may develop involving the Units and our common shares.
Read it in 10-K Feb 23, 2026 at sec.gov
RemovedRisk Factors
The FDA, other worldwide regulatory agencies, and notified bodies actively monitor compliance with local laws and regulations through review, inspection and audit of design and manufacturing practices, recordkeeping, reporting of adverse events, labeling and promotional practices. The FDA and other regulatory agencies worldwide can ban certain medical devices; detain or seize adulterated
Read it in 10-K Feb 25, 2025 at sec.gov
RewordedRisk Factors
Specifically, this final rule, The QMSR, which replaced the FDA expects to go into effect on February 2, 2026, establishes FDA’s former Quality System Regulation, sets forth the “Quality Management System Regulation”, which FDA’s cGMP requirements for medical devices, and among other things, incorporates by reference certain elements of the quality management system requirements of ISO 13485:2016.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
As of December 31, 2024, 2025, we had outstanding debt of $419.2 $149.0 million under our fourth amended and restated senior secured credit agreement (as amended, the “Third “Fourth Amended and Restated Credit Agreement”) and $346.2 Agreement”), $850.0 million of additional borrowing capacity available under the revolving credit facility. facility, and $110.6 million outstanding under the senior amortizing notes (the “Amortizing Notes”) component of our 6.50% tangible equity units (“Units”).
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Instead of requiring a medical device and its labeling to bear a UKCA mark, Instead, manufacturers would be required to assign a unique design identification (“UDI”) to a medical devices device and register the UDI in a publicly accessible database before they are the medical device is placed on the Great Britain market.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Medical devices must be safe and effective and must not compromise the clinical condition or safety of patients, or the safety and health of users and – where applicable – other persons, provided that any risks which may be associated with their use constitute acceptable risks when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety, taking into account the generally acknowledged state of the art.
Read it in 10-K Feb 23, 2026 at sec.gov
Show the other 42
RewordedRisk Factors
Some of our products products, and the related sales development, manufacturing and marketing development commercialization activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act (the “FDCA”), and by comparable agencies in foreign countries, and by or other regulatory agencies and governing bodies. bodies in the U.S. and around the world.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
All In the EU, medical devices placed on the market in must comply with the EU must meet Medical Devices Regulation, including the general safety and performance requirements laid down in Annex I to the EU Medical Devices Regulation, including the requirement which require that a medical device must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended purpose.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
For example, we may be subject to, among others, the requirements of the EU Corporate Sustainability Reporting Directive, other EU directives, EU and EU member state regulations, various disclosure requirements (such as information on greenhouse gas emissions, climate risks, use of offsets, and emissions reduction claims) and/or from the State of California as well as the SEC’s stayed rule on climate related disclosures, if put in place. California, pending ongoing litigation.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
There are currently different regulations in place in For example, Great Britain currently has a different regulatory framework for our products as compared to both Northern Ireland and the EU.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
However, one of the key topics in the MHRA’s recent consultation was to obtain feedback on whether MHRA intends to remove the requirement for a medical device and its labeling (i.e. packaging and instructions for use) in Great Britain to bear a physical UKCA mark.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
Most countries outside of the U.S. require that product approvals be renewed or recertified on a regular basis, generally every four to five years. years, in order for us to continue selling our products in those countries.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedRisk Factors
The continuing efforts of governments, insurance companies and other payors of healthcare costs to contain or reduce those costs could lead to patients being unable to obtain approval for payment from these third-party payors for procedures in which our products are used.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
On November 12, 2025 we issued 12,650,000 of our 6.50% tangible equity units (the “Units”) at a public offering price of $50.00 per Unit, for an aggregate offering of $632.5 million. We received proceeds of $613.1 million after the deduction of the underwriters fees and other issuance costs. Each Unit is comprised of a prepaid stock purchase contract and a senior amortizing note. Each amortizing note has a principal amount of $8.74 and bears interest at a rate of 6.30% per annum, with a final installment date of November 1, 2028 (“Amortizing Note”).
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
Unless settled early in accordance with the terms of the instruments, and subject to postponement in certain limited circumstances, each prepaid stock purchase contract will automatically settle on November 1, 2028 (the mandatory settlement date) for a number of shares of the Company’s common stock based on the arithmetic average of the volume weighted average price (“VWAPs”) of the Company’s common stock on each of the 20 consecutive trading days beginning on, and including, the 21st scheduled trading day immediately preceding November 1, 2028 ("Applicable Market Value") with reference to the following settlement rates:
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
Applicable Market Value Common Stock Issued Equal to or greater than $134.0842 0.3729 shares (minimum settlement rate) Less than $134.0842 but greater than $107.26 $50 divided by applicable market value Less than or equal to $107.26 0.4662 shares (maximum settlement rate)
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
The purchase contracts are mandatorily convertible into a minimum of 4.7 million shares or a maximum of 5.9 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 4.7 million minimum shares are included in the calculation of basic weighted average shares outstanding.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
The number of shares included in diluted weighted average shares outstanding related to these stock purchase contracts can vary each period, and is determined based on the Applicable Market Value in that reporting period, based on the above settlement rates. If the Applicable Market Value a reporting period is less than $134.0842 but greater than $107.26, then the number of shares included in diluted weighted average shares outstanding will be based on the weighted-average price per share of common stock over the twenty consecutive trading day period immediately preceding the balance sheet date, or November 1, 2028, for settlement of the stock purchase contracts.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
On June 27, 2025, we entered into the Fourth Amended and Restated Credit Agreement. The Fourth Amended and Restated Credit Agreement amends and restates, in its entirety, the Third Amended and Restated Credit Agreement dated as of December 31, 2019 (the “Third Agreement”). The Fourth Amended and Restated Credit Agreement provides for an aggregate credit facility of approximately $1.0 billion, comprised of a €65.3 million euro-denominated 5-year term loan facility (the “Euro Term Loans”), a $75.0 million U.S. dollar denominated 5-year term loan facility (the “U.S. Term Loans”), and an $850.0 million 5-year revolving credit facility (the “Revolving Facility”, and together with the Euro Term Loans and the U.S. Term Loans, collectively, the “Senior Credit Facilities”). The Senior Credit Facilities mature in June 2030 and include an uncommitted “accordion” feature pursuant to which the commitments thereunder may be increased by an additional $350.0 million in aggregate, subject to the satisfaction of certain customary conditions.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
On April 8, 2025, we acquired 100% of the outstanding stock of Keonn Technologies, S.L. (“Keonn”), a Barcelona, Spain-based leader in Radio-Frequency Identification (“RFID”) solutions for a purchase price of €64.8 million ($71.0 million), net of cash acquired, including €4.1 million ($4.5 million) estimated fair value of contingent consideration and €2.0 million ($2.2 million) related to a purchase price holdback. The purchase includes up to €20.0 million ($21.9 million) in contingent consideration payable upon the achievement of certain revenue targets through December 2027. In addition, we have granted equity totaling €9.0 million ($9.9 million) to Keonn employees. Keonn is included in the Medical Solutions reportable segment.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
Information pertaining to fiscal year 2023 results of operations, including a year-over-year comparison with fiscal year 2024, was included in our Annual Report on Form 10-K for the year ended December 31, 2024 under Part II, Item 7, “Management’s Discussion and Analysis of Financial Position and Results of Operations,” which was filed with the SEC on February 25, 2025.
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
2025 2024 Gross profit: Automation Enabling Technologies $ 239,506 $ 234,975 Medical Solutions 199,701 189,957 Unallocated (3,923) (3,387) Total $ 435,284 $ 421,545 Gross profit margin: Automation Enabling Technologies 47.8% 47.9% Medical Solutions 41.6% 41.4% Total 44.4% 44.4%
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
% Change 2025 2024 2025 vs. 2024 Research and development and engineering $ 95,484 $ 95,515 0.0% Selling, general and administrative 195,659 175,943 11.2% Amortization of purchased intangible assets 27,477 25,794 6.5% Restructuring, acquisition and related costs 22,652 13,709 65.2% Total $ 341,272 $ 310,961 9.7%
Read it in 10-K Feb 23, 2026 at sec.gov
AddedMD&A
On July 4, 2025, the U.S. enacted H.R.1 - One Big Beautiful Bill Act (the “Act”). The Act contains numerous income tax provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act and modifications to the international tax framework. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. We have evaluated the implications of the Act on our consolidated financial statements and related disclosures and have included the impact of items affecting our income tax expense for the twelve months ended December 31, 2025.
Read it in 10-K Feb 23, 2026 at sec.gov
RemovedMD&A
On January 2, 2024, we completed the acquisition of Motion Solutions Parent Corp. (“Motion Solutions”), an Irvine, California based provider of highly engineered integrated solutions, specializing in proprietary precision motion and advanced motion control solutions, for a total purchase price of $192.0 million in cash, net of working capital adjustments. The acquisition was financed with borrowings under our revolving credit facility. The addition of Motion Solutions enhances our product portfolio and further expands our presence in attractive medical and precision medicine applications. The Motion Solutions acquisition is included in our Medical Solutions reportable segment.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
During the fourth quarter of 2024, we updated our organizational structure and re-aligned our financial reporting structure under two reportable segments: Automation Enabling Technologies and Medical Solutions. Prior to the reorganization, our historical reportable segments were: Precision Medicine and Manufacturing, Robotics and Automation, and Medical Solutions. Prior period segment financial information has been recast to align with the new reportable segments.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
On March 27, 2020, we entered into an amendment (the “First Amendment”) to the Credit Agreement and exercised a portion of the uncommitted accordion feature. The First Amendment increased the revolving credit facility commitment under the Third Amended and Restated Credit Agreement by $145.0 million, from $350.0 million to $495.0 million, and reset the uncommitted accordion feature to $200.0 million for potential future expansion.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
On June 2, 2020, we entered into an amendment (the “Second Amendment”) to the Credit Agreement. The Second Amendment revised our consolidated leverage ratio definition (as defined in the Third Amended and Restated Credit Agreement) allowing for the
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
On October 5, 2021, we entered into an amendment (the “Fourth Amendment”) to the Credit Agreement to exercise the accordion feature. The Fourth Amendment increased the revolving credit facility commitment under the Third Amended and Restated Credit Agreement by $200.0 million, from $495.0 million to $695.0 million, and reset the uncommitted accordion feature to $200.0 million for potential future expansion.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
On March 10, 2022, the Company entered into an amendment (the “Fifth Amendment”) to the Credit Agreement to extend the maturity date thereof from December 31, 2024 to March 10, 2027, update the pricing grid, replace LIBOR with SOFR as the reference rate for U.S. dollar borrowings, and increase the uncommitted accordion feature from $200.0 million to $350.0 million.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
reporting unit include assets and liabilities which relate to the reporting unit’s operations. Additionally, reporting units that benefit from corporate assets or liabilities are allocated a portion of those corporate assets and liabilities on a proportional basis.
Read it in 10-K Feb 25, 2025 at sec.gov
RewordedMD&A
The net increase in cash and cash equivalents is primarily attributable to $614.4 million of proceeds from the issuance of tangible equity units, net of issuance costs paid, $82.8 million of borrowings under our Senior Credit Facilities, and cash provided by operating activities of $158.5 $64.1 million, and $198.0 million of borrowings under our revolving credit agreement, partially offset by $191.2 $365.7 million of debt repayments, $64.3 million of cash consideration for our 2025 acquisition, $39.3 million related to the 2024 acquisition, $131.1 million repurchase of debt repayments, $17.2 common shares, $15.6 million of capital expenditures, and $9.7 $7.8 million of payroll withholding tax payments related to net share settlement upon vesting of share-based compensation awards.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Net cash provided by financing activities was $56.9 $276.3 million in 2024, 2025, was primarily due to driven by proceeds from the issuance of tangible equity units, net of issuance costs, of $614.4 million, and borrowings under the credit facilities of $198.0 $82.8 million, partially offset by $131.1 $365.7 million of term loan and revolving credit facility repayments and $9.7 repayments, $39.3 million related to the repurchase of common shares, $7.8 million of payroll withholding tax payments related to net share settlement upon vesting of share-based compensation awards. awards, and $4.7 million of payments for debt issuance costs related to our senior credit facilities.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
The borrowings outstanding under the Senior Fourth Amended and Restated Credit Facilities Agreement bear interest at rates based on (a) the Base Rate, as Rate (as defined in the Fourth Amended and Restated Credit Agreement, Agreement) plus a margin ranging between 0.00% to zero and 0.75% per annum, determined by reference to the our consolidated leverage ratio, or (b) the Term SOFR Screen Rate, the Alternative Currency Daily Rate SOFR, SONIA or the Alternative Currency Term Rate, EURIBOR, as defined in the Credit Agreement, applicable, plus a margin ranging between 0.75% 1.00% and 1.75% per annum, determined by reference to our consolidated leverage ratio.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
The decrease in operating income was primarily due to an increase in R&D SG&A expenses of $7.7 $6.2 million, an increase in amortization expense of $7.1 million as a result of our 2024 acquisition, an increase in restructuring, acquisition and related costs of $5.6 $5.5 million, an increase in amortization expenses of $3.1 million as a result of our 2025 acquisition, and an increase in SG&A R&D expenses of $4.6 $1.2 million, partially offset by an increase in gross profit of $19.2 $9.7 million.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Medical Solutions Automation Enabling Technologies segment revenue in 2024 2025 increased $76.2 by $10.2 million, or 19.9%, 2.1%, versus 2023, 2024, primarily due to a $30.3 million increase in revenue from our 2024 acquisition, robotics and an increase in sales from our advanced surgery automation products, partially offset by a decrease $20.0 million decline in revenue from our precision medicine manufacturing products.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
This increase was primarily due to revenue from our 2024 acquisition, 2025 acquisition and an increase in revenue in the Automation Enabling Technologies segment, partially offset by a decrease in demand revenue in the advanced industrial and medical end markets. Medical Solutions segment excluding the impact of our 2025 acquisition.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
The decrease increase in operating income was primarily due to a decrease an increase in gross profit of $10.2 $4.5 million, and an increase a decrease in restructuring, acquisition and related costs of $6.8 $1.8 million, partially offset by a decrease in amortization expense of $4.7 $1.4 million, and a decrease in R&D expenses of $2.4 $1.2 million, and a decrease partially offset by an increase in SG&A expenses of $0.7 $0.9 million.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Medical Solutions segment revenue in 2024 2025 increased $76.2 $21.1 million, or 19.9%, 4.6%, versus 2023, 2024, primarily due to revenue from our 2024 acquisition, and an driven by a $33.7 million increase in sales revenue from our advanced surgery products, partially offset by a decrease $12.6 million decline in revenue from our precision medicine products.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
In the event Likewise, should we determine that we are will not be able to realize all or part of our net deferred tax assets in the future in excess of their net recorded amounts, future, an adjustment to the valuation allowance for the deferred tax assets would will be recorded and would increase will reduce our net income in the period in which such determination is made.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
The increase decrease in net interest expense was primarily due to an increase in the weighted average interest rate, partially offset by a decrease in average debt levels under our senior credit facilities. and a decrease in the weighted average interest rate.
Read it in 10-K Feb 23, 2026 at sec.gov
RewordedMD&A
Amortization of purchased intangible assets, excluding the amortization of developed technologies that is included in cost of revenue, was $27.5 million, or 2.8% of revenue, in 2025, versus $25.8 million, or 2.7% of revenue, in 2024, versus $20.4 million, or 2.3% of revenue, in 2023. 2024.
Read it in 10-K Feb 23, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NOVT/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.